Clinical Trial Update: A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

A Phase 1, randomized, single-blind, four-period cross-over, placebo-controlled, dose-escalation study in healthy Japanese subjects evaluating safety and pharma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• GR181413A/AT1001

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 1 | Status: COMPLETED